TScan Therapeutics

TCRX

Market cap $120M

Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025

WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.28 per share a year ago.

Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.

WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 4, 2025 at 4:55 p.m. Eastern Time.

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago.

Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended March 31, 2025, and provided a corporate update.

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually.

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time.

Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience